NH lawmakers override marijuana greenhouse veto; Study: Medical cannabis helps sleep; Study: Psilocybin boosts mental health; Rescheduling op-ed
Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day.
Your support makes Marijuana Moment possible…
Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there.
Support our work at https://www.patreon.com/marijuanamoment
/ TOP THINGS TO KNOW
Bipartisan members of Congress sent a letter pressing President Donald Trump and key Cabinet members for guidance on how marijuana rescheduling will affect consumers and businesses—including whether there are plans to cover medical cannabis under Medicare.
New Hampshire lawmakers overrode Gov. Kelly Ayotte’s (R) veto of a bill to allow medical cannabis companies to cultivate in greenhouses, which supporters say will make marijuana more affordable for patients.
A new study found that “supervised use of full-spectrum medical cannabis oil was associated with favorable patient-reported perceptions of quality of life and sleep.”
- “Higher cannabis oil concentrations and longer treatment duration were associated with higher odds of better outcomes.”
A new federally funded study published by the American Medical Association found that “people receiving state-regulated psilocybin services in Oregon experienced few safety events, high satisfaction with services, and overall improvements in mental health, wellbeing, and life satisfaction.”
- “While many participants did not seek services specifically to address mental health, they reported decreases in depression, anxiety, and posttraumatic stress disorder symptoms; improved life satisfaction; and improved mental wellbeing that met the threshold for statistical significance.”
Robert A. Mikos of Vanderbilt University Law School argues in a new Marijuana Moment op-ed that Attorney General Todd Blanche’s citation of international drug treaties in his partial cannabis rescheduling order suggests the Trump administration may not follow through with broader reform beyond medical use.
- “Trump himself has never called for relaxing federal controls on adult-use marijuana.”
/ FEDERAL
National Institute on Drug Abuse Director Nora Volkow said that “the notion that cannabis is not addictive may basically be incorrect.”
The National Highway Traffic Safety Administration is highlighting a public education campaign to deter cannabis-impaired driving.
/ STATES
Oklahoma lawmakers are conducting an interim study on medical cannabis testing and transparency.
The Vermont Department of Health reported a decline in high school and middle school student marijuana use.
Tennessee is missing out on more than $54 million dollars in tax revenue due to hemp product restrictions.
Michigan regulators filed complaints against marijuana businesses over alleged violations.
Oregon regulators will consider a marijuana business violation stipulated settlement agreement on Thursday.
—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.
Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—
/ INTERNATIONAL
Thailand’s government is warning dentists not to issue cannabis prescriptions without examining, diagnosing or providing treatment to individual patients.
/ SCIENCE & HEALTH
A review highlighted the “multifactorial antidepressant potential of CBD and its analogues, suggesting a possible role as adjuvant or alternative therapies in mood disorders.”
A review concluded that “cannabinoids improve sleep quality and duration with acceptable safety, offering a potential alternative for managing insomnia.”
/ ADVOCACY, OPINION & ANALYSIS
NORML is surveying cannabis consumers about their favorite legal brands.
/ BUSINESS
Aurora Cannabis Inc. is urging its shareholders to take no action on Curaleaf Holdings, Inc.’s unsolicited take-over bid until its board of directors makes a formal recommendation.
Johnson & Johnson is reportedly set to lead Delix Therapeutics’s $85 million Series C funding round.
IM Cannabis Corp. announced its intent to complete a 30:1 share consolidation in order to meet conditions to trade on the Nasdaq Capital Market.
Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox.
Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
